Literature DB >> 17111191

Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors.

Christian Hagel1, Ulrich Zils, Matthias Peiper, Lan Kluwe, Stefan Gotthard, Reinhard E Friedrich, David Zurakowski, Andreas von Deimling, Victor Felix Mautner.   

Abstract

The differences in the clinical course and histopathology of sporadic and neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) were investigated retrospectively. The collective comprised 38 NF1 patients and 14 sporadic patients. NF1 patients were significantly younger at diagnosis (p<0.001) and had a significantly shorter survival time than sporadic patients (median survival 17 months vs. 42 months, Breslow p<0.05). The time interval to local recurrence and metastatic spread was also significantly shorter in NF1 patients (9.4 months vs. 30.0 months, p<0.01; 9.1 months vs. 33.2 months, p<0.001, respectively). In patients with the original histopathological data available (22 NF1 patients, 14 sporadic cases), NF1-associated MPNST showed a significantly higher cellularity compared to sporadic tumors (p<0.001) whereas sporadic MPNST featured a significantly higher pleomorphism (p<0.01). Most importantly, while histopathological variables correlated with French Fédération Nationale des Centres de Lutte Contre le Cancer grading in sporadic MPNST, this was not the case for NF1-associated tumors. The differences between NF1-associated and sporadic MPNST in regard to the clinical course and histopathology may reflect some fundamental differences in biology and pathomechanism of the two tumor groups. Our findings indicate the necessity for a separate grading scheme which takes into account the genetic background in NF1 patients.

Entities:  

Mesh:

Year:  2006        PMID: 17111191     DOI: 10.1007/s11060-006-9266-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  21 in total

1.  NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors.

Authors:  A Perry; K A Roth; R Banerjee; C E Fuller; D H Gutmann
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; Y Ino; M B Moller; A E Rosenberg; D N Louis
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 3.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

Authors:  D H Gutmann; A Aylsworth; J C Carey; B Korf; J Marks; R E Pyeritz; A Rubenstein; D Viskochil
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

4.  Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors.

Authors:  Trude Holmeide Agesen; Vivi Ann Flørenes; Willemina M Molenaar; Guro E Lind; Jeanne-Marie Berner; Boudewijn E C Plaat; Rudy Komdeur; Ola Myklebost; Eva van den Berg; Ragnhild A Lothe
Journal:  J Neuropathol Exp Neurol       Date:  2005-01       Impact factor: 3.685

5.  Malignant peripheral nerve sheath tumours associated with von Recklinghausen's neurofibromatosis.

Authors:  R C Ramanathan; J M Thomas
Journal:  Eur J Surg Oncol       Date:  1999-04       Impact factor: 4.424

6.  Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models.

Authors:  J E DeClue; S Heffelfinger; G Benvenuto; B Ling; S Li; W Rui; W C Vass; D Viskochil; N Ratner
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

7.  Malignant peripheral nerve sheath tumors in neurofibromatosis 1.

Authors:  A A King; M R Debaun; V M Riccardi; D H Gutmann
Journal:  Am J Med Genet       Date:  2000-08-28

8.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1.

Authors:  D G R Evans; M E Baser; J McGaughran; S Sharif; E Howard; A Moran
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

9.  Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors.

Authors:  Mark A Watson; Arie Perry; Tarik Tihan; Richard A Prayson; Abhijit Guha; Julia Bridge; Rosalie Ferner; David H Gutmann
Journal:  Brain Pathol       Date:  2004-07       Impact factor: 6.508

10.  The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases.

Authors:  J Costa; R A Wesley; E Glatstein; S A Rosenberg
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

View more
  19 in total

1.  Intrathoracic Malignant Peripheral Nerve Sheath Tumor: Histopathological and Immunohistochemical Features.

Authors:  Megha Ralli; Sunita Singh; Sonia Hasija; Renuka Verma
Journal:  Iran J Pathol       Date:  2015

2.  Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor.

Authors:  Q Fan; J Yang; G Wang
Journal:  Clin Transl Oncol       Date:  2013-06-08       Impact factor: 3.405

3.  Lymph node metastasis of malignant peripheral nerve sheath tumor in the absence of widespread disease five years after diagnosis: a rare finding.

Authors:  Gwendolyn J Godfrey; Hanan Farghaly
Journal:  Int J Clin Exp Pathol       Date:  2010-10-02

4.  A retroperitoneal NF1-independent malignant peripheral nerve sheath tumor with elevated serum CA125: case report and discussion.

Authors:  Bing Yan; Xianze Meng; Bian Shi; Jun Shi; Zhifeng Qin; Pinkang Wei
Journal:  J Neurooncol       Date:  2012-04-19       Impact factor: 4.130

5.  Podoplanin and CD34 in peripheral nerve sheath tumours: focus on neurofibromatosis 1-associated atypical neurofibroma.

Authors:  Urs Naber; Reinhard E Friedrich; Markus Glatzel; Victor Felix Mautner; Christian Hagel
Journal:  J Neurooncol       Date:  2010-09-07       Impact factor: 4.130

6.  Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors.

Authors:  Helge R Brekke; Matthias Kolberg; Rolf I Skotheim; Kirsten S Hall; Bodil Bjerkehagen; Björn Risberg; Henryk A Domanski; Nils Mandahl; Knut Liestøl; Sigbjørn Smeland; Håvard E Danielsen; Fredrik Mertens; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2009-01-30       Impact factor: 12.300

Review 7.  Neurofibromatosis type 1 and associated malignancies.

Authors:  Kaleb Yohay
Journal:  Curr Neurol Neurosci Rep       Date:  2009-05       Impact factor: 5.081

8.  Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors.

Authors:  Slawomir Antoszczyk; Samuel D Rabkin
Journal:  Expert Opin Orphan Drugs       Date:  2015-12-26       Impact factor: 0.694

9.  Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.

Authors:  David E Reuss; Jana Mucha; Christian Hagenlocher; Volker Ehemann; Lan Kluwe; Victor Mautner; Andreas von Deimling
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

10.  Clinical characteristics predicting internal neurofibromas in 357 children with neurofibromatosis-1: results from a cross-selectional study.

Authors:  Emilie Sbidian; Smaïl Hadj-Rabia; Vincent M Riccardi; Laurence L Valeyrie-Allanore; Sébastien Barbarot; Olivier Chosidow; Salah Ferkal; Diana Rodriguez; Pierre Wolkenstein; Sylvie Bastuji-Garin
Journal:  Orphanet J Rare Dis       Date:  2012-09-03       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.